INTENT Biologics
- Company typePrivate
- Founded2025
- HeadquartersRochester, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
INTENT Biologics firmographics
Firmographics- Name
- INTENT Biologics
- Legal name
- INTENT Biologics, Inc.
- Website
- https://intent.bio
- Company type
- Private
- Founded year
- 2025
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
INTENT Biologics industry classification
Industry- Product category
- Regenerative Biologics / Advanced Wound Care Therapeutics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Regenerative Immunology & Inflammation Modulation (pro-regenerative biologics) (HLAAAGAL)
- akta.pro secondary industries
- Exosome & Extracellular Vesicle (EV) Therapeutics (HLAMANAE), Biologic API/Drug Substance Manufacturing Services (HLAAAKAA)
Keywords
Where INTENT Biologics is headquartered
LocationHeadquarters
- HQ city
- Rochester
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
INTENT Biologics business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Revenue model
- PEP Biologic™ Commercialization: INTENT Biologics is a clinical-stage biotechnology company with no current revenue. The company is advancing PEP Biologic through Phase 3 clinical trials toward BLA submission for multiple chronic wound indications. Revenue generation is expected upon regulatory approval and commercialization of its exosome-based therapeutic.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels6 records
INTENT Biologics product offering
Product offeringCore offering
INTENT Biologics is a clinical-stage biotechnology company developing PEP Biologic™ (Purified Exosome Product), a first-in-class topical regenerative biologic therapy that delivers hundreds of billions of platelet-derived exosomes to sites of injury or inflammation. The product is being advanced through Phase 3 clinical trials for multiple chronic wound indications including diabetic foot ulcers, chronic radiation ulcers, pressure ulcers, surgical wounds, and venous leg ulcers.
Product overview
INTENT Biologics is a clinical-stage biotechnology company operating as a platform biotechnology focused on exosome-based therapeutics. The company's core product is PEP Biologic™ (Purified Exosome Product), a first-in-class topical regenerative biologic that delivers platelet-derived exosomes for advanced wound healing. PEP Biologic™ is being developed across multiple chronic wound indications (Diabetic Foot Ulcers, Radiation Ulcers, Pressure Ulcers, Surgical Wounds, and Venous Leg Ulcers) and represents a platform technology with a polyvaltent mechanism of action that promotes angiogenesis, regulates inflammation, stimulates cell proliferation, and enhances cytoprotection.
Differentiator
Problem solved
Functional benefit
Brands
- PEP Biologic: Purified Exosome Product - a first-in-class topical biologic therapy capable of promoting rapid tissue repair and modulating immune responses for advanced wound healing.
Products and services
- PEP Biologic™ (Purified Exosome Product) A first-in-class topical regenerative biologic therapy delivering hundreds of billions of highly potent platelet-derived exosomes directly to targeted tissue sites to promote rapid tissue repair, modulate immune responses, and facilitate healing across multiple chronic wound indications including diabetic foot ulcers, chronic radiation ulcers, pressure ulcers, surgical wounds, and venous leg ulcers. Currently in clinical development for healthcare institutions and specialty providers.
Quantifiable outcome
- Phase 2 DFU trial: 54% healing vs 25% standard care at 12 weeks
- +2 more outcomes
Companies that use INTENT Biologics
Customer profileNamed customers1 record
Segments6 records
Ideal customer profiles3 records
INTENT Biologics technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
INTENT Biologics partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered minor and core.
- OU HealthminorOU Health physician Dr. treated a complex radiation wound using INTENT Biologics' investigational regenerative therapy, reporting clinical success. This represents early clinical adoption and validation of the technology in a real-world setting.
- RIONcoreINTENT Biologics was formed as a strategic spinout from RION, the global leader in exosome biomanufacturing. INTENT licensed the rights to PEP Biologic™ from RION for therapeutics in advanced wound care in 2025. RION developed the proprietary exosome biomanufacturing process and continues to manufacture for INTENT. RION holds the only scaled exosome production capability in the world.
- Mayo CliniccoreOver two decades of Mayo Clinic research discovered that regenerative healing is driven primarily by exosomes, not stem cells. RION licensed the exosome IP/technology from Mayo Clinic in 2017. INTENT holds a worldwide license to this proprietary technology. Mayo Clinic advisors provide ongoing scientific and clinical guidance.
Scale indicators16 records
Recent moves7 records
Expansion highlights6 records
INTENT Biologics competitors and assessment
Company assessmentDirect peers
- Direct Biologics: Direct Biologics develops ExoFlo, an exosome-based regenerative therapy, including for wound care and inflammatory indications. It is the closest direct peer to INTENT Biologics, operating in the same exosome-therapeutic category with overlapping wound healing applications.
- Capricor Therapeutics: Capricor Therapeutics is developing exosome-based therapeutics (CAP-2003 and related programs) for inflammatory and regenerative indications. It is a direct peer in the exosome therapeutic modality with a similar strategy of leveraging cell-derived vesicles for inflammation modulation.
- Evox Therapeutics: Evox Therapeutics is a clinical-stage biotech engineering exosomes for delivery of therapeutic payloads in inflammatory and rare diseases. It is a direct peer in the engineered-exosome therapeutic category and competes for the same scientific and investor mindshare.
Emerging players
- RION: RION is the parent company of INTENT Biologics and the global leader in exosome biomanufacturing, holding the only scaled exosome production process. It is comparable both as the upstream manufacturing platform that enables INTENT and as a peer developer of exosome-based therapeutics in adjacent indications.
- Organicell Regenerative Medicine: Organicell develops exosome-based regenerative products (e.g., Zofin) targeting inflammatory and degenerative conditions. It is an emerging peer with overlapping modality and inflammatory-disease focus, though at an earlier commercialization stage.
- Codiak BioSciences: Codiak BioSciences pioneered engineered exosome therapeutics (engEx platform) for oncology and inflammatory diseases. Although now restructured, it remains a relevant historical peer in the engineered exosome therapeutic space that validates the modality INTENT is pursuing.
Broad incumbents
- Organogenesis: Organogenesis is a leading commercial-stage regenerative medicine company (Apligraf, Dermagraft, PuraPly, etc.) focused on advanced wound care. It is a broad incumbent with a deep wound-care sales force and hospital-channel reach that INTENT would compete with or partner alongside upon PEP Biologic approval.
- Smith+Nephew: Smith+Nephew is a global medical device and wound care incumbent (advanced wound management, negative pressure wound therapy, skin substitutes). It is a broad incumbent defining the standard of care across the wound indications PEP Biologic is targeting and would be a logical partner or acquirer.
- MiMedx: MiMedx is a regenerative medicine company selling placental-tissue-based wound care products (EpiFix, AmnioFix) used in diabetic foot ulcers and other chronic wounds. It is a broad incumbent commercial-stage competitor in the same advanced wound care market segments.
- Convatec: Convatec is a global medical products company with a sizable advanced wound care franchise (AQUACEL, InnovaMatrix). It is a broad incumbent in the wound care channel that would shape formulary access and reimbursement dynamics for PEP Biologic upon launch.
Market position
Strengths1 record
Weaknesses1 record
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
INTENT Biologics social profiles
Digital presenceINTENT Biologics financial estimates
Financial estimateRevenue estimate
Valuation estimate
INTENT Biologics leadership team
Management profileNumber of profiles
Profiles7 records
INTENT Biologics funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
INTENT Biologics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about INTENT Biologics
What does INTENT Biologics do?
INTENT Biologics is a clinical-stage biotechnology company developing PEP Biologic™ (Purified Exosome Product), a first-in-class topical regenerative biologic therapy that delivers hundreds of billions of platelet-derived exosomes to sites of injury or inflammation. The product is being advanced through Phase 3 clinical trials for multiple chronic wound indications including diabetic foot ulcers, chronic radiation ulcers, pressure ulcers, surgical wounds, and venous leg ulcers.
Is INTENT Biologics a public or private company?
INTENT Biologics is a private company. It is classified as corporate owned and is currently operating.
When was INTENT Biologics founded?
INTENT Biologics was founded in 2025. It employs 1 to 10 people.
Where is INTENT Biologics based?
INTENT Biologics is headquartered in Rochester, United States, in the North America region.
How does INTENT Biologics make money?
One revenue line is on record: PEP Biologic™ Commercialization.
Who are INTENT Biologics's main competitors?
Direct peers on record are Direct Biologics, Capricor Therapeutics and Evox Therapeutics. Emerging players are RION, Organicell Regenerative Medicine and Codiak BioSciences. Broad incumbents are Organogenesis, Smith+Nephew, MiMedx and Convatec.
Does INTENT Biologics have an API?
No public API is recorded for INTENT Biologics.
What industry is INTENT Biologics in?
INTENT Biologics's product category is Regenerative Biologics / Advanced Wound Care Therapeutics. Its primary akta.pro industry code is HLAAAGAL, Regenerative Immunology & Inflammation Modulation (pro-regenerative biologics), with a secondary code of HLAMANAE, Exosome & Extracellular Vesicle (EV) Therapeutics. Its NAICS code is 325414 and its SIC code is 2836.